HK Stock Movement | CLOUDBREAK-B (02592) Rises Over 4% Intraday, Gains 80% in a Week as Company Accelerates Global Commercialization of CBT-009

Stock News

Dec 02

CLOUDBREAK-B (02592) surged over 4% intraday, extending its weekly gains to more than 80%. At the time of writing, the stock was up 2.71% at HK$8.72, with a turnover of HK$6.75 million.

The company recently announced that its wholly-owned subsidiary, ADS Therapeutics LLC (ADS USA), incorporated in Delaware, U.S., has successfully obtained patents in Japan and Europe for its core product CBT-009. These patents mark a significant milestone in CBT-009's development, enhancing its global reach and commercialization prospects.

CLOUDBREAK-B expects to collaborate with major pharmaceutical firms to establish licensing agreements for the production, development, and distribution of CBT-009 in Japan and Europe—key high-end markets for the product. Such partnerships are anticipated to accelerate CBT-009's global commercialization potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1188054588"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188054588\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188054588?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-02 10:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188054588","market":"fut","top_or_hot":-1,"title":"HK Stock Movement | CLOUDBREAK-B (02592) Rises Over 4% Intraday, Gains 80% in a Week as Company Accelerates Global Commercialization of CBT-009","media":"Stock News","content":"<p>CLOUDBREAK-B (02592) surged over 4% intraday, extending its weekly gains to more than 80%. At the time of writing, the stock was up 2.71% at HK$8.72, with a turnover of HK$6.75 million.</p>\n<p>The company recently announced that its wholly-owned subsidiary, ADS Therapeutics LLC (ADS USA), incorporated in Delaware, U.S., has successfully obtained patents in Japan and Europe for its core product CBT-009. These patents mark a significant milestone in CBT-009's development, enhancing its global reach and commercialization prospects.</p>\n<p>CLOUDBREAK-B expects to collaborate with major pharmaceutical firms to establish licensing agreements for the production, development, and distribution of CBT-009 in Japan and Europe—key high-end markets for the product. Such partnerships are anticipated to accelerate CBT-009's global commercialization potential.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | CLOUDBREAK-B (02592) Rises Over 4% Intraday, Gains 80% in a Week as Company Accelerates Global Commercialization of CBT-009</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | CLOUDBREAK-B (02592) Rises Over 4% Intraday, Gains 80% in a Week as Company Accelerates Global Commercialization of CBT-009\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-02 10:28</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CLOUDBREAK-B (02592) surged over 4% intraday, extending its weekly gains to more than 80%. At the time of writing, the stock was up 2.71% at HK$8.72, with a turnover of HK$6.75 million.</p>\n<p>The company recently announced that its wholly-owned subsidiary, ADS Therapeutics LLC (ADS USA), incorporated in Delaware, U.S., has successfully obtained patents in Japan and Europe for its core product CBT-009. These patents mark a significant milestone in CBT-009's development, enhancing its global reach and commercialization prospects.</p>\n<p>CLOUDBREAK-B expects to collaborate with major pharmaceutical firms to establish licensing agreements for the production, development, and distribution of CBT-009 in Japan and Europe—key high-end markets for the product. Such partnerships are anticipated to accelerate CBT-009's global commercialization potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CBT","symbol_name":"卡博特","start_time":0,"source_url":"","article_id":"1188054588","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188054588","pubTimestamp":1764642491,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CLOUDBREAK-B (02592) surged over 4% intraday, extending its weekly gains to more than 80%. At the time of writing, the stock was up 2.71% at HK$8.72, with a turnover of HK$6.75 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CBT":"卡博特","BK1161":"生物科技","02592":"拨康视云-B","BK4090":"商品化工"},"translate_title":"港股动向|CLOUDBREAK-B(02592)盘中涨超4%公司加速CBT-009全球商业化一周涨80%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02592":1,"CBT":1},"content_text":"CLOUDBREAK-B (02592) surged over 4% intraday, extending its weekly gains to more than 80%. At the time of writing, the stock was up 2.71% at HK$8.72, with a turnover of HK$6.75 million.\nThe company recently announced that its wholly-owned subsidiary, ADS Therapeutics LLC (ADS USA), incorporated in Delaware, U.S., has successfully obtained patents in Japan and Europe for its core product CBT-009. These patents mark a significant milestone in CBT-009's development, enhancing its global reach and commercialization prospects.\nCLOUDBREAK-B expects to collaborate with major pharmaceutical firms to establish licensing agreements for the production, development, and distribution of CBT-009 in Japan and Europe—key high-end markets for the product. Such partnerships are anticipated to accelerate CBT-009's global commercialization potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}